Efficacy and Safety of Checkpoint Inhibitor Treatment in Patients with Advanced Renal or Urothelial Cell Carcinoma and Concomitant Chronic Kidney Disease: A Retrospective Cohort Study
<i>Background</i>: Checkpoint inhibitors are a standard of care in the treatment of advanced renal cell carcinoma (RCC) and urothelial carcinoma (UC). Patients with these tumors often suffer from concomitant chronic kidney disease (CKD). Limited data are available on the efficacy and tox...
Main Authors: | Florian Seydel, Susanne Delecluse, Martin Zeier, Tim Holland-Letz, Georg Martin Haag, Anne Katrin Berger, Barbara Christine Grün, Nina Bougatf, Markus Hohenfellner, Stefan Duensing, Dirk Jäger, Stefanie Zschäbitz |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2021-04-01
|
Series: | Cancers |
Subjects: | |
Online Access: | https://www.mdpi.com/2072-6694/13/7/1623 |
Similar Items
-
Renal Collecting Duct Carcinoma and Concomitant Bladder Urothelial Carcinoma: A Case Report
by: Hsi-Lin Hsiao, et al.
Published: (2008-03-01) -
Research Progress on the Effect of Clinical Concomitant Medication on Efficacy of Immune Checkpoint Inhibitors in Urothelial Carcinoma
by: LYU Zhengqin, et al.
Published: (2024-03-01) -
Urothelial carcinoma; an overview of histology, molecular subtypes, and clinical implications based on the latest WHO classification
by: Fateme Khalatbari, et al.
Published: (2023-09-01) -
Complete Response of Rare Sarcomatoid Upper Tract Urothelial Carcinoma Variant: Case Report and Literature Review
by: Syah Mirsya Warli, et al.
Published: (2023-05-01) -
Primary Urothelial Carcinoma of the Anterior Urethra
by: McGeorge Stephen, et al.
Published: (2019-12-01)